RJMty19 / Ruishun Bio - LARVOL DELTA

A Phase 1 Study of RJMty19: Anti-CD19 Humanized CAR-Engineered Allogeneic Double Negative T Cells in Adults with B-Cell Non-Hodgkin's Lymphoma (ASH 2023) - P1 | "All patients received lymphodepleting chemotherapy with fludarabine and cyclophosphamide...Furthermore, five patients had prior BTKi therapy and four patients had prior lenalidomide/venetoclax therapy before recruiting into the trial... As of July 31 2023, 15 patients with B-NHL were enrolled and 12 patients were evaluable (including one subject finished infusion for just 10 days). Of the 11 patients who had completed DLT evaluations at Day 28, five (45.5%) were male, and the average age was 59.7 years (range 45-74). At baseline, 73% of patients with IPI score ≥ 3 (range 0-4); the median volume of target lesion was 169,000 (4520-513,688) mm3."

Clinical • P1 data • Anemia • B Cell Non-Hodgkin Lymphoma • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology

A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Guangdong Ruishun Biotech Co., Ltd

New P1 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: RenJi Hospital

New P1 trial • ANCA Vasculitis • Fibrosis • Immunology • Inflammatory Arthritis • Lupus • Myositis • Scleroderma • Systemic Lupus Erythematosus • Systemic Sclerosis • Vasculitis

RJMty19-B-NHL002: A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Guangdong Ruishun Biotech Co., Ltd

New P1 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology